Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Fig. 1

Patient disposition. All numbers expressed are in thousands. *Excludes abatacept. Based on MacLean’s positive predictive value of an administrative data-based algorithm for the identification of patients with RA [29]. b/tsDMARDs, biologic or targeted synthetic disease-modifying antirheumatic drugs; RA, rheumatoid arthritis

Back to article page